DESTINY-Breast04:Calm Thinking on the HER2-low  

作　　者：Qingliang JIANG Jie TANG Xianglin LIU Yingjie JIANG Yanfang LIU Hengyu LI 

机构地区：[1]The First Affiliated Hospital of Naval Medical University,Shanghai 200433,China [2]Daiichi Sankyo(China)Holdings Co.,Ltd.,Shanghai 200040,China

出　　处：《Clinical Cancer Bulletin》2022年第3期160-163,共4页临床癌症通报（英文）

摘　　要：The DESTINY-Breast04(DB-04)trial is a phaseⅢclinical trial that examined the efficacy of trastuzumab deruxtecan(T-DXd),an anti-HER2-antibody drug,in patients with low HER2 expression(HER2-low)advanced breast cancer.The study enrolled patients with HER2-low,unresectable,and/or recurrent metastatic breast cancer(mBC)who were resistant to previous endocrine therapy and had received one or two previous lines of chemotherapy.Among the 557 enrolled patients,494(88.7%)patients had hormone receptor-positive(HR+)mBC and 63(11.3%)patients had hormone receptor-negative(HR−)mBC.

关 键 词：HER2-low T-DXd metastatic breast cancer 

分 类 号：R730.5[医药卫生—肿瘤]